CSS Announces Licensing Deal with Mammoth

Barkby Group PLC
19 September 2023

Barkby Group PLC


("Barkby" or the "Company")



Cambridge Sleep Sciences Announces Licensing Deal with Mammoth



Barkby (AIM: BARK) announces that its subsidiary, Cambridge Sleep Sciences, ("CSS") the science-based sleep technology business behind SleepEngine®, has granted a five-year global license, (the "Agreement") to Mammoth International Ltd., ("MIL") enabling it to manufacture a Smart Mattress using CSS's SleepEngine® platform.


Under the terms of the Agreement, MIL will incorporate CSS's sleep technology into a new Smart Mattress product line it has developed. For each CSS-enabled mattress MIL produces, it will pay CSS a royalty of £75 per single mattress and £150 per double mattress.


MIL's Smart Mattress product line will be launched at the end of September with manufacturing commencing within the next six months. It expects to produce approximately 5,000 mattresses in the year following launch.


Dr Julian Stone, CEO of CSS, said: 

"We're delighted to be working with Mammoth, helping it to enhance its product range with a new Smart Mattress. Mammoth has strong credentials, particularly in specialist health and sport mattresses and our technology is a natural extension of their design ethos."


SleepEngine® technology has been developed and refined over more than a decade by a team of researchers, scientists, sound and medical experts. The result is a unique audio solution that helps to retrain the brain to restore healthy natural sleep patterns, a key component for mental, physical, and cognitive wellbeing. SleepEngine® technology offers a unique integration opportunity with existing or new third-party products capable of delivering high quality audio.


Mammoth International Ltd is a new UK based subsidiary of the Mammoth Comfort Group set up to take advantage of new technologies at the medical end of mattress design.


CSS remains in advanced negotiations with several household names on a number of new multi-year enterprise licensing deals for its SleepEngine® technology. Further announcements will be made as soon as practicable when these licences are signed.


- Ends -


For more information


Barkby Group plc

Charles Dickson, Executive Chairman


c/o Montfort

Cavendish Capital Markets Limited (Nomad and Broker)

Carl Holmes and Simon Hicks (Corporate Finance)

Tim Redfern (ECM)


+44 (0)20 7220 0500


Olly Scott

Georgia Colkin


+44 (0)78 1234 5205



About Barkby

Barkby is a roadside real estate business focused on building and scaling a high-quality portfolio of modern, ESG-compliant assets. It is in the process of exiting its non-core investments.



About Cambridge Sleep Sciences Ltd

Cambridge Sleep Sciences Ltd, part of the Life Sciences division of The Barkby Group Plc, develops technology which improves natural sleep. Using the principles of neuroscience and cutting-edge technology to enhance brain activity during sleep, its innovative solutions aim to improve health, wellbeing and enhance quality of life. 


Its SleepEngine® technology has been developed and refined over a decade by a team of researchers, scientists, sound engineers and medical experts. This unique technology produces sounds which emulate the waves created by the brain during sleep cycles. The sleep sounds guide the user's brain through the sequence of healthy sleep cycles, helping them fall asleep and achieve the quality of sleep they need in a consistent and optimal way.


Find out more at: www.cambridgesleepsciences.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings